Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Birte,Wistinghausen

第一单位： Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC.;Center for Cancer and Immunology Research, Children's National Research Institute, Children's National Hospital, Washington, DC.;The George Washington University School of Medicine and Health Sciences, Washington, DC.

作者： Birte,Wistinghausen ^[1] ; Keri,Toner ^[1] ; Donald A,Barkauskas ^[2] ; Lauren P,Jerkins ^[3] ; Hannah,Kinoshita ^[4] ; Pamela,Chansky ^[5] ; Gloria,Pezzella ^[6] ; Lauren,Saguilig ^[7] ; Robert J,Hayashi ^[8] ; Harshal,Abhyankar ^[9] ; Brooks,Scull ^[9] ; Vivekanudeep,Karri ^[10] ; Jay,Tanna ^[6] ; Patrick,Hanley ^[1] ; Michelle L,Hermiston ^[11] ; Carl E,Allen ^[9] ; Catherine M,Bollard ^[1]

作者单位： Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC.;Center for Cancer and Immunology Research, Children's National Research Institute, Children's National Hospital, Washington, DC.;The George Washington University School of Medicine and Health Sciences, Washington, DC. ^[1] Department of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA.;Children's Oncology Group Statistics and Data Center, Monrovia, CA. ^[2] Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN. ^[3] Center for Cancer and Immunology Research, Children's National Research Institute, Children's National Hospital, Washington, DC.;The George Washington University School of Medicine and Health Sciences, Washington, DC.;Department of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA. ^[4] The George Washington University School of Medicine and Health Sciences, Washington, DC. ^[5] Center for Cancer and Immunology Research, Children's National Research Institute, Children's National Hospital, Washington, DC. ^[6] Children's Oncology Group Statistics and Data Center, Monrovia, CA. ^[7] Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO. ^[8] Baylor College of Medicine, Texas Children's Hospital Cancer Center, Houston, TX. ^[9] Rush Medical College, Chicago, IL. ^[10] Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA. ^[11]

主题词人类(Humans);儿童(Child);疱疹病毒4型, 人(Herpesvirus 4, Human);爱泼斯坦巴尔病毒感染(Epstein-Barr Virus Infections);T淋巴细胞(T-Lymphocytes);淋巴组织增殖性疾病(Lymphoproliferative Disorders)

DOI 10.1182/bloodadvances.2023010832

PMID 38163318

发布时间 2024-11-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood advances

2024年8卷5期

1116-1127页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.

Blood advances

相似文献

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.

Blood advances

相似文献

Blood advances

相关期刊

检索历史清除